Recently, the 2019 China traditional Chinese medicine brand building conference and China traditional Chinese medicine brand press conference hosted by China traditional Chinese Medicine Association was held in Beijing, releasing the list of "China traditional Chinese medicine brand building action plan" and "China traditional Chinese medicine brand 2019". The list of traditional Chinese medicine brands released at the meeting includes 8 genuine Chinese medicine brands, 2 ecological and green Chinese medicine brands, 7 high-quality Chinese medicine Yinpian brands, 3 unique processed Chinese medicine Yinpian brands, 10 classic heritage Chinese medicine brands and 20 clinically valuable Chinese medicine brands.

Among them, based on the project research of "brand value promotion of traditional Chinese medicine and biopharmaceutical" and "Clinical Application guide of traditional Chinese medicine for treatment of dominant diseases", 20 brand products of traditional Chinese medicine with clinical value, including zhizhikang capsule, are listed in the list of "brand of traditional Chinese medicine with clinical value" released by evaluation standards, expert evaluation and other standards.

Taking the treatment and management of dyslipidemia as an example, zhizhikang, originated from Hongqu, is recognized as a natural lipid regulating drug at home and abroad. According to the relevant person in charge of AstraZeneca, zhizhikang has accumulated a large number of clinical data over the past 20 years since its listing, including large-scale clinical evidence-based medicine studies such as China coronary heart disease secondary prevention study (CCSPS), which have confirmed that zhizhikang is more effective, less adverse reactions, milder and safer in regulating lipid and reducing the incidence of cardiovascular events. Zhizhikang, a natural lipid regulating drug, is made of special red koji fermented by modern technology. It contains 13 kinds of natural statins and their homologues, together with flavonoids, ergosterol and unsaturated fatty acids, to play a comprehensive role in lipid regulation.

According to the introduction, the China Association of traditional Chinese medicine will continue to carry out brand research based on the action plan for brand building of traditional Chinese medicine and the platform of Chinese traditional Chinese medicine brand cluster development alliance. It plans to cultivate 100-200 Chinese traditional Chinese medicine brands in 5 years, evaluate and release 200-300 Chinese traditional medicine brands, establish and improve the brand cultivation and evaluation standard system of traditional Chinese medicine industry, and establish Chinese medicine in China Brand database; launch brand cultivation, brand value promotion, time-honored traditional Chinese medicine enterprises and product rejuvenation plan of traditional Chinese medicine products; strengthen the construction of China traditional Chinese medicine brand cluster development alliance; regularly recommend Chinese traditional Chinese medicine brand to international standardization organization, China brand construction and Development Promotion Association and other institutions to become an international or national brand; create the most influential Chinese traditional medicine brand at home and abroad A grand gathering.

Source:http://finance.eastmoney.com/a/201912111320451716.html

Time:2019.12.11